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In this issue of Pflügers Archiv—European Journal of
Physiology, Okumura et al. present a new association between
the serotonin and the GLP-1 system which, in turn, impacts
serum insulin levels. In detail, they show a link between
HTR4 activity in GLP-1 and PYY positive murine ileal epi-
thelial cells and plasma levels of GLP-1 in mice. They first
performed immunofluorescence staining to analyze HTR ex-
pression in murine ileum and colon. They found significant
expression of HTR2A, HTR2B, and HTR4 expression in ep-
ithelial cells of both tissues. Interestingly, in the ileum, HTR4
was found in enteroendocrine (EE) L cells, a group of EE cells
in the small intestine, which are also positive for GLP-1 and
PYY as well as for serotonin (5-HT) expression. To validate
these data, the authors also isolated small intestinal crypts
from mice and cultured the dissociated cells. Here they could
confirm that HTR4 positive cells co-express GLP-1 and PYY.
These observations lead to the reasonable assumption that
HTR4 signaling might affect GLP-1 and/or PYY release from
these enteroendocrine L cells. In order to determine a potential
association between HTR4 signaling and GLP-1 release, the
authors monitored plasma GLP-1 levels from mice treated
either intraperitoneally or intragastrically with the established
selective HTR4 agonist tegaserod. Under these “basal condi-
tions,” no effects of the HTR4 agonist on serum GLP-1 levels
were detectable. However, when lipid-induced increase of se-
rum GLP-1 levels was mimicked by administration of so-
called Intralipos, a soybean oil emulsion, intragastric
administration of tegasteron 30 min before significantly re-
duced Intralipos-induced increases of serum GLP-1 levels.
This effect was inhibited by the co-administration of the
HTR4 antagonist RS39604 confirming the importance of
HTR4 signaling for this process. Interestingly, intraperitoneal
administration of tegasteron failed to block Intralipos-induced
increases of serum GLP-1 levels.
GLP-1 together with the gastric inhibitory polypeptide
(GIP) are the two principle incretin hormones. Incretins are
metabolic hormones that are released after eating and de-
creased blood glucose by augmentation of insulin secretion
from pancreatic beta cells of the islets of Langerhans.
Incretins are responsible for the observation that intravenous
injection of glucose leads to less insulin secretion compared
with oral glucose administration: the so-called incretin effect.
Given the strong interaction between the GLP-1 system and
insulin/glucose serum levels, it is not surprising that the GLP-
1 system is involved in pathological states such as type 2
diabetes, obesity, and non-alcoholic fatty liver disease
(NAFLD) [1–4]. Hence, synthetic GLP-1 receptor agonists
such as liraglutide (Victoza) have been approved for medical
use in Europe in 2009 and in the USA in 2010.
The new association between the serotonin and the
GLP-1 system which impacts serum insulin levels as
shown here opens up a new avenue to positively manip-
ulate the GLP-1 system and as a secondary effect serum
insulin levels under pathological conditions. The most in-
triguing part of this new strategy is the observation that
HTR4 agonists affect serum GLP-1 levels only when in-
creased by lipids and when applied intragastrically. This
kind of specificity is responsible for the fact that the most
wanted effects occur exactly at the desired time point:
shortly after food uptake. Thus, it will be an enlightening
and important task for upcoming studies to firstly reveal
whether HTR4 signaling affects serum GLP-1 and thus
insulin levels in humans and, secondly, whether these ef-
fects are beneficial for patients with type 2 diabetes.
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